Chicago, IL – Biopharmaceutical research-funding organization CQDM is joining the Massachusetts Life Sciences Center (MLSC) in a new initiative to create an International Collaborative Industry Program (ICIP). This initiative will support the establishment of partnerships between Massachusetts and Quebec-based life sciences companies for research and development of new products and processes intended for commercialization.
This program is dedicated to late-stage R&D companies from different sectors such as biotechnology, pharmaceuticals, medical devices, diagnostics and bioinformatics to submit project applications. For this ICIP competition, the winning Quebec companies will be eligible for funding up to $2 million. CQDM funds 50% of the Quebec portion of the project to a maximum of $ 500,000; companies will match the funding that CQDM provides. The MLSC will provide each winning Massachusetts company with up to $500,000 in matching funding. Detailed information on the CQDM / MLSC funding program is available on CQDM’s website.
“No one country or region can solve the challenge of developing the next generation of drugs and medical devices on its own,” said Susan Windham-Bannister, Ph.D., president & CEO of the MLSC. “The breakthroughs of tomorrow will only be possible through collaboration like that which we are fostering between Massachusetts and Quebec.”
CQDM is funded by Pfizer Canada, AstraZeneca, Merck, Boehringer Ingelheim (Canada) Ltd., GlaxoSmithKline Inc., Eli Lilly Canada Inc., Novartis Pharmaceuticals Canada Inc., the Business-Led Networks of Centres of Excellence (BL-NCE) and the Ministère de l’Enseignement supérieur, de la Recherche, de la Science et de la Technologie du Québec.